The MPP’s patents and licences database, MedsPaL, is a resource that provides information on the intellectual property status of selected HIV, hepatitis C, tuberculosis and other patented essential medicines in low- and middle-income countries.
Geneva, 3 October 2018. The Medicines Patent Pool (MPP) and ViiV Healthcare - a global specialist company - signed an extension of their licensing agreement in July 2018, to further increase access to key antiretroviral dolutegravir (DTG) for adults living with HIV in Mongolia and Tunisia. This amendment allows generic manufacturers to supply low-cost quality-assured DTG and combinations in the two countries.
DTG-based regimens have been recommended by the World Health Organization as the preferred first-line treatment for people living with HIV, including adults and adolescents as well as children for whom there is approved DTG dosing. Notably, TLD (tenofovir disoproxil fumarate/lamivudine/dolutegravir) is a new convenient once-daily single-tablet regimen for adults and adolescents. DTG is also an important option in other lines of therapies.
“The MPP has worked with long-standing partner ViiV Healthcare since 2014, when the initial licensing agreement was signed. But that was just a starting point”,...
MPP Statement at the World Health Organisation on 1er October:
The Medicines Patent Pool (MPP) would like to thank the tripartite (the WHO, the FAO and the OIE) for the opportunity to provide inputs to the global framework for development and stewardship to combat antimicrobial resistance (AMR).
We would like to welcome that the framework, in line with the mandate of the Political Declaration of the United Nations High-Level Meeting on AMR, includes a number of basic principles for needs-driven research and development (R&D) that foster access to new products. These principles should contribute to guiding the design of appropriate incentives to strengthen the current antibiotic pipeline. As stated in the declaration and the framework, those incentives should be designed in a manner that de-link the financing of R&D from the price and volume of sales of new antibiotics to facilitate equitable and affordable access and to avoid perverse incentives that lead to excessive use. And we agree to the n...
The Medicines Patent Pool (MPP) welcomes the opportunity to provide inputs to the Draft Roadmap on access to medicines and vaccines.
We note that one of the deliverables considered as potentially having significant impact on access to safe, effective and affordable medicines is supporting the expansion of the MPP to essential medicines under patent. This expansion is in fact already in process.
The MPP was established by Unitaid as a mechanism to promote innovation and access to medicines through public health-oriented licensing. It is a concrete example in moving towards Universal Health Coverage by enabling over 100 countries to get faster access to new HIV, hepatitis C and TB treatments at affordable prices and in suitable formulations.
With the support of the Swiss Development and Cooperation Agency, the MPP recently undertook a feasibility study to assess the potential for the MPP’s patent pooling model to be applied to patented essential medicines in other therapeutic areas. Following strong s...
“WHO welcomes the announcement that the Medicines Patent Pool is expanding its mandate to include patented medicines on WHO’s Model List of Essential Medicines in its patent pooling and voluntary licensing initiatives. It is a welcome and significant step f...”
Unable to load twitter timeline, please allow cookie